Iron isomaltoside 1000
- Generic Name
- Iron isomaltoside 1000
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 1370654-58-2
- Unique Ingredient Identifier
- 3M6325NY1R
- Background
Iron isomaltoside 1000 is under investigation in Iron Deficiency Anaemia. Iron isomaltoside 1000 has been investigated for the treatment and basic science of Anemia, Gastric Cancer, Esophageal Cancer, Chronic Kidney Disease, and Anemia, Iron-Deficiency, among others.
- Associated Conditions
- Iron Deficiency (ID), Iron Deficiency Anemia (IDA)
- Associated Therapies
- -
Safety and Efficacy Extension Study of Iron Isomaltoside 1000 (Monofer®) in Subjects With Inflammatory Bowel Disease
- First Posted Date
- 2011-08-05
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- Pharmacosmos A/S
- Target Recruit Count
- 39
- Registration Number
- NCT01410435
- Locations
- 🇭🇺
Hungary, Hungary, Hungary
🇦🇹Austria, Austria, Austria
A Randomized, Comparative, Open-label Study of IV Monofer® Administered as Maintenance Therapy by Single or Repeated Bolus Injections in Comparison With IV Iron Sucrose in Subjects With CKD-5D
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-10-18
- Last Posted Date
- 2015-12-02
- Lead Sponsor
- Pharmacosmos A/S
- Target Recruit Count
- 351
- Registration Number
- NCT01222884
- Locations
- 🇮🇳
Jatin Kothari, Mumbai, India
Open-label PK Study of Iron Isomaltoside 1000 (Monofer) Administered by 500 mg IV Injection or 1000 mg IV Infusion to Patients With Inflammatory Bowel Disease
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-10-04
- Last Posted Date
- 2013-11-14
- Lead Sponsor
- Pharmacosmos A/S
- Target Recruit Count
- 16
- Registration Number
- NCT01213680
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous to Patients With CKD
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-10-04
- Last Posted Date
- 2013-11-14
- Lead Sponsor
- Pharmacosmos A/S
- Target Recruit Count
- 16
- Registration Number
- NCT01213992
A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-06-16
- Last Posted Date
- 2015-12-03
- Lead Sponsor
- Pharmacosmos A/S
- Target Recruit Count
- 350
- Registration Number
- NCT01145638
- Locations
- 🇮🇳
Apollo Hospitals, New Delhi, India
Iron Isomaltoside 1000 (Monofer®) in Non-Dialysis Dependent Chronic Kidney Disease and With Renal-Related Anaemia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-04-13
- Last Posted Date
- 2015-12-03
- Lead Sponsor
- Pharmacosmos A/S
- Target Recruit Count
- 351
- Registration Number
- NCT01102413
- Locations
- 🇩🇰
Pharmacosmos, Holbaek, Denmark
Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia
- First Posted Date
- 2009-11-20
- Last Posted Date
- 2012-11-27
- Lead Sponsor
- Pharmacosmos A/S
- Target Recruit Count
- 350
- Registration Number
- NCT01017614
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath